Phaseline

Targets › DENV2

DENV2: drug programs, companies and trials

4 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Immunology; next expected readout Dec 2027.

Open in Phaseline: the race on DENV2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Sao Paulo General HospitalDengue 1,2,3,4 (attenuated) vaccine
Live attenuated tetravalent dengue vaccine (DENV-1, DENV-3, DENV-4, and chimeric DENV-2)
DENV1, DENV2, DENV3, DENV4Phase 4Rheumatoid Arthritis (RA)Dec 2027
Beth KirkpatrickTV005
Live attenuated tetravalent dengue vaccine (rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, rDEN4Δ3
DENV1, DENV2, DENV3, DENV4Phase 2Dengue–
Beth KirkpatrickrDEN2Δ30-7169 attenuated virus strain
Live attenuated DENV-2 virus strain with 30 nucleotide deletion in 3' UTR (derived from To
DENV2Phase 2Dengue–
National Institute of Allergy and Infectious Diseases (NIAID)rDEN2delta30-7169
Live attenuated dengue virus 2 with 30-nucleotide deletion in 3' UTR
DENV2Phase 1Healthy VolunteersNov 2028

Conditions

Dengue (2) Healthy Volunteers (1) Rheumatoid Arthritis (RA) (1)

Modalities

mixed (2), protein or peptide (1), other (1)

Companies

Beth Kirkpatrick (2) National Institute of Allergy and Infectious Diseases (NIAID) (1) University of Sao Paulo General Hospital (1)

Related targets

DENV1 (2) DENV3 (2) DENV4 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.